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• Rabies is a zoonotic viral 
infectious disease. 
• It is caused by RNA viruses 
in the family Rhabdoviridae, 
Genus Lyssavirus, most 




• Rabies occurs in more than 
150 countries and territories 
around the world. 
• According to the WHO, there 
are more than 59,000 deaths 
caused by rabies per year 
globally
• over 95% of the cases occur 




A: Human deaths from 
rabies 
B: Death rates per
capita (per 100,000
population)
(WHO Expert consultation on rabies TRS n°1012, 2017)
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• Rabies in the 
U.S.
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• Rabies is transmitted by 
the bite or scratch of rabid 
animals but may also 
result from non-bite 
exposures
• The symptoms of rabies at 
the first stage may be 
nonspecific 
• Clinical signs will progress 
to other neurological signs
https://www.mountsinai.org/health-library/diseases-conditions/rabies
7
• Once clinical signs appear, there is no effective 
treatment for rabies.
• This is a significant global public health concern, 
particularly for people who are at risk.
• Rabies can be prevented by vaccination in both 









• To design data preparation workflow that is ready to use 
for statistical evaluation from Rabies Laboratory Kansas 
State University and to create the protocol of data 
preparation
• To develop interprofessional teamwork and 
communication skills virtually during to the COVID-19 
pandemic situation
• To communicate risk of rabies and vaccination to animal 
handling personnel by creating a summary and a poster
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Background
• The Rabies Laboratory of Kansas State University is the 
primary diagnostic lab for the states of Kansas and 
Nebraska.  
• The tests measuring rabies antibodies includes;
- Fluorescent Antibody Virus Neutralization (FAVN) test 
- Rapid Fluorescent Focus Inhibition Test (RFFIT) 
- Enzyme-linked immunosorbent assay (ELISA) 
• Both the ACIP and the WHO recommend the RFFIT to be 
the current gold standard serological assay for rabies. 
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RFFIT
• The RFFIT test is recommended for measuring 
post-vaccination immune responses and for 








An example of a microscopic field 
where virus has been neutralized
An example of a microscopic field 
where virus was not neutralized
https://www.cdc.gov/rabies/specific_groups/hcp/serology.html
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Activities performed and 
products developed
Preparing human 
laboratory data for 
statistical evaluation
Summary of the process 
of preparing a set of 
human laboratory data 
for statistical evaluation
Summary of the best 
practices for rabies 
vaccination and booster 
timing for personnel 
handling animals
Poster for educating 
animal handling staff on 
rabies control and 
prevention
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Preparing human laboratory data 
for statistical evaluation
16
Template for Human Laboratory Data for Statistical Evaluation


















• Sources of data
1. VetView
-The laboratory information management system (LIMS) 
-The excel spreadsheet is a report generated by VetView
containing all the results such as patient name, date of 
draw, results, etc. 
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REF_CASE_NO RESULT_VALUE ACCESSION_NO RECEIVED_DATE SAMPLED_DATE
ITEM_NU
MBER ANIMAL_ID REF_CASE_NO TEST_CODE RESULT_VALUE STATUS_CODE
CVC-186 >/= 0.5 IU/mL R15-026537 9/1/2015 3:42:15.820000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-186 RFF-1033 >/= 0.5 IU/mL F
CVC-185 >/= 0.5 IU/mL R15-026538 9/1/2015 3:42:17.367000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-185 RFF-1033 >/= 0.5 IU/mL F
CVC-184 >/= 0.1 IU/mL R15-026539 9/1/2015 3:42:18.913000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-184 RFF-1033 >/= 0.1 IU/mL F
CVC-183 >/= 0.5 IU/mL R15-026540 9/1/2015 3:42:20.523000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-183 RFF-1033 >/= 0.5 IU/mL F
CVC-181 >/= 0.1 IU/mL R15-026542 9/1/2015 3:42:23.757000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-181 RFF-1033 >/= 0.1 IU/mL F
CVC-179 >/= 0.5 IU/mL R15-026544 9/1/2015 3:42:26.975000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-179 RFF-1033 >/= 0.5 IU/mL F
CVC-178 >/= 0.5 IU/mL R15-026545 9/1/2015 3:42:28.835000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-178 RFF-1033 >/= 0.5 IU/mL F
CVC-177 >/= 0.5 IU/mL R15-026546 9/1/2015 3:42:30.600000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-177 RFF-1033 >/= 0.5 IU/mL F
CVC-176 >/= 0.5 IU/mL R15-026547 9/1/2015 3:42:32.288000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-176 RFF-1033 >/= 0.5 IU/mL F
CVC-175 >/= 0.5 IU/mL R15-026548 9/1/2015 3:42:34.319000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-175 RFF-1033 >/= 0.5 IU/mL F
CVC-174 >/= 0.5 IU/mL R15-026549 9/1/2015 3:42:36.256000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-174 RFF-1033 >/= 0.5 IU/mL F
CVC-173 >/= 0.5 IU/mL R15-026550 9/1/2015 3:42:38.178000 PM
8/29/2015 12:00:00.000000 
AM 1 XXX XXXX CVC-173 RFF-1033 >/= 0.5 IU/mL F
CVC-172 >/= 0.1 IU/mL R15-026551 9/1/2015 3:42:40.022000 PM
8/29/2015 12:00:00.000000 




date which each 
sample was drawn
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2. The completed rabies titer submission forms called 
“Rabies Serology for Vaccine Titer Response by RFFIT 
Screen Method for Human Specimen Only” 
-The forms are electronically completed by each participant 
per rabies titer event and printed at the event for signature 
and sample processing. 









Regions in the United States classified by United States 
Department of Health and Human Services
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Tube ID (Name or ID#)Client First Client Last Address City State Zip Phone # Fax # Email Tube ID (Name or ID#)Date of DrawTest ordered (RFFIT screen or RFFIT endpoint)Sample ype
AVMA-3997 XXX XXXX XXXXXXXXXX XXX Texas XXXXX XXXXXXX 0 XX@XX AVMA-39977/13/2018 RFF-1033 SERUM
AVMA-4095 XXX XXXX XXXXXXXXXX XXX South DakotaXXXXX XXXXXXX 0 XX@XX AVMA-40957/13/2018 RFF-1033 SERUM
AVMA-3993 XXX XXXX XXXXXXXXXX XXX Arizona XXXXX XXXXXXX 0 XX@XX AVMA-39937/13/2018 RFF-1033 SERUM
AVMA-3935 XXX XXXX XXXXXXXXXX XXX Colorado XXXXX XXXXXXX 0 XX@XX AVMA-39357/13/2018 RFF-1033 SERUM
AVMA-3933 XXX XXXX XXXXXXXXXX XXX New York XXXXX XXXXXXX 0 XX@XX AVMA-39337/13/2018 RFF-1033 SERUM
AVMA-4024 XXX XXXX XXXXXXXXXX XXX Illinois XXXXX XXXXXXX 0 XX@XX AVMA-40247/13/2018 RFF-1033 SERUM
AVMA-4041 XXX XXXX XXXXXXXXXX XXX Colorado XXXXX XXXXXXX 0 XX@XX AVMA-40417/13/2018 RFF-1033 SERUM
AVMA-4049 XXX XXXX XXXXXXXXXX XXX New MexicoXXXXX XXXXXXX 0 XX@XX AVMA-40497/13/2018 RFF-1033 SERUM
AVMA-4072 XXX XXXX XXXXXXXXXX XXX Florida XXXXX XXXXXXX 0 XX@XX AVMA-40727/13/2018 RFF-1033 SERUM
AVMA-3938 XXX XXXX XXXXXXXXXX XXX New MexicoXXXXX XXXXXXX 0 XX@XX AVMA-39387/13/2018 RFF-1033 SERUM
AVMA-3900 XXX XXXX XXXXXXXXXX XXX Colorado XXXXX XXXXXXX 0 XX@XX AVMA-39007/13/2018 RFF-1033 SERUM
AVMA-4079 XXX XXXX XXXXXXXXXX XXX North CarolinaXXXXX XXXXXXX 0 XX@XX AVMA-40797/13/2018 RFF-1033 SERUM
AVMA-3983 XXX XXXX XXXXXXXXXX XXX Texas XXXXX XXXXXXX 0 XX@XX AVMA-39837/13/2018 RFF-1033 SERUM
AVMA-3992 XXX XXXX XXXXXXXXXX XXX Wisconsin XXXXX XXXXXXX 0 XX@XX AVMA-39927/13/2018 RFF-1033 SERUM
AVMA-3932 XXX XXXX XXXXXXXXXX XXX Maine XXXXX XXXXXXX 0 XX@XX AVMA-39327/13/2018 RFF-1033 SERUM
Conference 
number
3. Excel spreadsheet files which are compiled 


































AVMA-3997 xxx xxxx xxx xxx Texas xxxxx xxxxx 0 xxxxx
AVMA-









AVMA-4095 xxx xxxx xxx xxx
South 
Dakota xxxxx xxxxx 0 xxxxx
AVMA-
4095 7/13/2018 RFF-1033 SERUM R18-031710 0 1986 8
AVMA-
4095 7/13/2018 2.4 IU/mL 2013 N/A N/A N/A N/A N/A N/A N/A N/A N/A
August 
2013
AVMA-3993 xxx xxxx xxx xxx Arizona xxxxx xxxxx 0 xxxxx
AVMA-




IU/mL 1998 N/A N/A N/A N/A N/A N/A N/A N/A N/A 1998
AVMA-3935 xxx xxxx xxx xxx Colorado xxxxx xxxxx 0 xxxxx
AVMA-



















AVMA-3933 xxx xxxx xxx xxx New York xxxxx xxxxx 0 xxxxx
AVMA-




IU/mL 2015 N/A N/A N/A N/A N/A N/A N/A N/A N/A 2015
AVMA-4024 xxx xxxx xxx xxx Illinois xxxxx xxxxx 0 xxxxx
AVMA-




IU/mL 2006 N/A N/A N/A N/A N/A N/A N/A N/A N/A
January 
2006
AVMA-4041 xxx xxxx xxx xxx Colorado xxxxx xxxxx 0 xxxxx
AVMA-








AVMA-4049 xxx xxxx xxx xxx
New 
Mexico xxxxx xxxxx 0 xxxxx
AVMA-








Data from 2. submission forms 
Data from 1. VetView
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ID
An example of prepared 
human laboratory data 
for statistical evaluation 
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Summary of the process of 
preparing a set of human 




• The template that the evaluators designed 
needed to be adjusted to make it consistent 
with the data collected.
• The submission forms were not scanned in 
order. 
– This could be solved by scanning the submission 
form in order.
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• For long term use, using available technology 
with the submission forms could help to make 
it less complicated.
– Electronic signature
• Some of the participants could not remember 
when they were vaccinated 
– In the future, if vaccination can be recorded and 
the participants can access the information online, 
this could be another way to solve this problem. 
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Summary of the best practices for rabies vaccination 
and booster timing for personnel handling animals
Introduction
Post-exposure prophylaxis (PEP)
• For previously vaccinated people
• For previously unvaccinated people
Pre-exposure prophylaxis (PrEP)
 Primary vaccination 
 Booster vaccination










Number and Competency Description
4
Interpret results of data analysis for public health 
research, policy, or practice
For the prepared human laboratory data for 
statistical evaluation, data previously collected was 
transcribed into an anonymous data table.
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Apply principles of leadership, governance and 
management, which include creating a vision, 
empowering others, fostering collaboration and 
guiding decision making
In many places where personnel handling animals 
are not aware about rabies, the summary and poster 
that I created will help empower personnel to have 
better understanding and awareness of rabies.
18
Select communication strategies for different 
audiences and sectors
The step-by-step summary of the process of preparing 
a set of human laboratory data for statistical 
evaluation.    
Creating the poster for educating animal handling staff 
on rabies control and prevention.
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Number and Competency Description
19
Communicate audience-appropriate public health 
content, both in writing and through oral 
presentation
Creating the summary of the process of preparing a set 
of human laboratory data for statistical evaluation and 
a summary of the best practices for rabies vaccination 
and booster timing for personnel handling animals. 
The poster for educating animal handling staff on 
rabies control and prevention for communicating with 
different audiences at worksites.
21 Perform effectively on interprofessional teams
Working with the evaluators from University of 
Washington School of Public Health.
32
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